City
Epaper

New generation of Covid vax shows promising results

By IANS | Published: August 26, 2022 4:27 PM

Stockholm, Aug 26 A team of researchers is developing a coronavirus vaccine designed to be less sensitive to ...

Open in App

Stockholm, Aug 26 A team of researchers is developing a coronavirus vaccine designed to be less sensitive to mutations and will likely be equipped for future strains.

As per a study, published in the journal EMBO Molecular Medicine, the vaccine showed promising results in mice, and the researchers now hope to be able to take it to safety studies on humans.

"The idea is that it will give broader protection that more resembles that gained after an actual infection and will be a bit more future-proof than the vaccines currently in use," said researcher Matti Sallberg, professor at Karolinska Institutet in Sweden.

In this newly published study, the researchers show that the vaccine protects mice against serious infection from the beta variant of SARS-CoV-2, a variant that can evade the immune response, and activates immune cells (T cells) that recognise the coronavirus found in bats.

Different types of vaccines have been highly instrumental in impeding the pandemic caused by the coronavirus SARS-CoV-2. One challenge is the virus mutability, which is to say, its ability to change to avoid the human defence response.

Most current vaccines are based on using parts of the coronavirus's so-called spike protein to trigger the body's immune response to the virus. It is a good vaccine protein to use, but unfortunately, it is the spike protein where frequent mutations occur, which can impact the vaccines' effectiveness.

The researchers are, therefore, developing a vaccine containing more parts of the virus, including ones that do not mutate at the same rate as the spike protein.

The vaccine is a DNA vaccine, which means that it comprises DNA sequences that, when injected into the body, make the cells produce the proteins that the DNA sequences contain instructions for, the researchers said.

In this case, it concerns DNA for parts of the spike protein from three different coronavirus variants and DNA for another two virus proteins, called M and N, where mutations are less common.

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Matti sallbergswedenStockholmKarolinska InstitutetEmbo molecular medicine
Open in App

Related Stories

InternationalRussia-Ukraine War: Vladimir Putin Vows to Deploy Troops Along Finland Border After It Joins NATO

InternationalSweden's War Warning Triggers Panic Buying, Prepares Citizens for Potential Conflict

InternationalCanada, Sweden, Ukraine, and UK File Complaint Against Iran Over 2020 Plane Crash

BusinessVi collaborates with Truecaller to add trust and safety to their customer communication

PoliticsSecurity Council renews mandate of UN Hodeidah mission

Health Realted Stories

Health'Curbing insulin resistance can help prevent or delay diabetes'

HealthIndia played key role in adoption of health regulations at World Health Assembly: Centre

HealthProlonged use of AC may raise risk of dry skin, asthma attacks: Doctors

HealthYour socioeconomic status may determine risk of diabetes, depression, cancer

HealthNew influenza B antibody will help develop universal vaccine: US scientists